Is Atossa Therapeutics going out of business?

ATOSSA THERAPEUTICS, INC. (ATOS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ATOSSA THERAPEUTICS, INC. (ATOS) scores 18 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Filing event risk: Going-Concern Warning (-8 pts)

Five questions, kept separate

Survival - Fragile

8-13 mo of estimated runway from 2026-06-30, based on $26.1M of cash and short-term investments against $29.8M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

123.8% burn burden support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -107.71%
• Price / Earnings: Unprofitable (see Valuation)
• Cash Runway (years): 0.88y
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-07.

Price as of 2026-09-07.